STRS Ohio’s Theravance Biopharma TBPH Stock Holding History

STRS Ohio’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$709K	Buy	43,700 +7,400	+20%	+$131K	﹤0.01%	838
2025 Q4	$679K	Sell	36,300 -7,800	-18%	-$129K	﹤0.01%	855
2025 Q3	$644K	Buy	+44,100	New	+$557K	﹤0.01%	886
2023 Q3	–	Sell	-32,900	Closed	-$340K	–	2044
2023 Q2	$340K	Buy	32,900 +16,600	+102%	+$183K	﹤0.01%	1434
2023 Q1	$176K	Hold	16,300	–	–	﹤0.01%	1621
2022 Q4	$182K	Buy	+16,300	New	+$171K	﹤0.01%	1613
2016 Q4	–	Sell	-3,700	Closed	-$134K	–	1991
2016 Q3	$134K	Buy	+3,700	New	+$103K	﹤0.01%	1621
2014 Q4	–	Sell	-2,950	Closed	-$68K	–	1801
2014 Q3	$68K	Buy	+2,950	New	+$85.6K	﹤0.01%	1612

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio's TBPH Position: Q1 2026 in Review

STRS Ohio increased its Theravance Biopharma (TBPH) stake by 20% in Q1 2026, buying an estimated $131K and bringing the position to 43,700 shares worth $709K. The position accounts for ﹤0.01% of the portfolio, ranked #838.

STRS Ohio first reported a position in TBPH in Q3 2014 and has held it in 8 quarters since. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

STRS Ohio held 43,700 shares of Theravance Biopharma worth $709K as of Q1 2026.
STRS Ohio bought 7,400 Theravance Biopharma shares in Q1 2026, an estimated $131K.
Theravance Biopharma made up ﹤0.01% of STRS Ohio's portfolio in Q1 2026, its #838 holding.
STRS Ohio first reported a position in Theravance Biopharma in Q3 2014 and has held it in 8 quarters since.
173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.